Research team

Laboratory Experimental Medicine and Pediatrics (LEMP)

Expertise

type 1 diabetes continue glucose monitoring autoimmune polyendocrine syndromes

The impact of a patient-tailored multi-biomarker device to improve glucose control for people with type 1 diabetes. 01/11/2020 - 31/10/2022

Abstract

In type 1 diabetes mellitus (T1DM), insulin-producing beta-cells of the pancreas are being destroyed, resulting in excessive glucose levels and permanent need of insulin therapy. Living with T1DM is challenging. It requires intensive monitoring of glycaemia and titration of insulin in order to obtain near-normal glycaemia to reduce the risk of complications. More and more people with T1DM are being treated with insulin pumps and continuous glucose monitoring (CGM) sensors. CGM improves metabolic control and quality of life and decreases hypoglycaemia. However, currently available CGM devices also have shortcomings. They do not warn about impending ketoacidosis and do not provide information on lactate levels which can be produced during intensive exercise. Adding lactate and ketones to the equation will provide additional information on glucose fluctuations. There is an urgent need for a patient-tailored multi-biomarker device to protect against hypoglycaemia or ketoacidosis, to improve quality of life and to increase the possibilities to exercise freely. The latter is important as people with T1DM often do not perform exercise because of fear of hypoglycaemia. The main research question of this project is to evaluate the added value of measuring other biomarkers (ketones, lactate) besides glucose, in people with T1DM in daily life, but also while performing different types of exercise (anaerobic, aerobic). This will result in better algorithms to improve glycaemic control.

Researcher(s)

Research team(s)

Relation between residual beta cell function and glycemic variability in (pre)type 1 diabetes. 01/01/2011 - 31/12/2014

Abstract

The established clinical network and the developed dynamic function tests and biological markers provide us with the unique opportunity to identify sufficiently large groups of high-risk first-degree relatives (> 50% risk of diabetes) of a proband with type 1 diabetes and of recent-onset type 1 diabetic patients with the overall aim to investigate the correlation between functional beta cell mass and glycemic variability in relation to metabolic outcome in order to determine thresholds of residual function below which: - glucose tolerance starts to decline sharply in relatives - the risk of deteriorating metabolic control and (severe) hypoglycemic events strongly increases in patients

Researcher(s)

Research team(s)